腫瘍臨床試験の世界市場2020-2027:フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV)、研究デザイン別(介入、観察、アクセス拡大)、がん種類別、地域別

◆英語タイトル:Oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Cancer Type, By Region, And Segment Forecasts, 2020 - 2027
◆商品コード:GV20NV095
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2020年9月21日
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥654,500見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥764,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥984,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、腫瘍臨床試験の世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場要因・動向・範囲、フェーズ別市場規模(フェーズI、フェーズII、フェーズIII、フェーズIV)、研究デザイン別市場規模(介入、観察、アクセス拡大)、がん種類別市場規模(肺がん、乳がん、甲状腺がん、白血病、肝臓がん)、地域別市場規模、競争分析などの項目を掲載しています。
・調査手法・範囲
・エグゼクティブサマリー
・市場要因・動向・範囲
・腫瘍臨床試験の世界市場規模:フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV)
・腫瘍臨床試験の世界市場規模:研究デザイン別(介入、観察、アクセス拡大)
・腫瘍臨床試験の世界市場規模:がん種類別(肺がん、乳がん、甲状腺がん、白血病、肝臓がん)
・腫瘍臨床試験の世界市場規模:地域別
・競争分析
【レポートの概要】

Oncology Clinical Trials Market Growth & Trends

The global oncology clinical trials market size is expected to reach USD 16.6 billion by 2027, expanding at a CAGR of 5.4%, according to a new report by Grand View Research, Inc. Increasing number of cancer cases and deaths due to the disease and rising demand for precision and personalized medicine to cure the disease is boosting the market growth.

The burden of cancer continues to increase due to the aging population and increasing adoption of behavioral patterns, mostly the sedentary lifestyle, dietary changes with an inclination towards junk foods, as well as smoking. In the last few years, oncology research has seen an increased focus on targeted therapies and personalized medicine. There has been a steady rise in the novel therapeutic approaches and oncology clinical trials owing to the continuous advances and shift in treatment modalities towards targeted anti-cancer drugs.

Clinical research has become an important element to address the global burden of cancer in improving the patient’s life. As per the 2019 report of IQVIA Institute for Human Data Science, out of the top 33 big pharmaceutical firms, 28 firms are developing anti-cancer molecules. The drug pipeline depicts no signs of slackening down. There are more than 600 firms that are having one or more drugs in the late-stage drug development for cancer.

Besides, the innovations in this field are also driving the market. Better insight into the etiology and classification of different types of tumors has led to a shift in the strategies of oncology treatment. Innovation is a prominent trend in oncology drug development. This is seen in the rise in the number of first-in-class drugs entering the market since 2015.

Oncology Clinical Trials Market Report Highlights

• The phase II segment dominated the market with a share of 45.8% in 2019. This is attributed to the increasing number of applications for Phase II

• The interventional design segment accounted for the largest share of 87.9% in 2019 due to the increasing number of drugs in interventional studies

• North America held 55.0% of the market share in 2019. Favorable government initiatives and the presence of a large number of players in the U.S. offering advanced services are responsible for market growth

• In Asia Pacific, the market is expected to witness the fastest CAGR of 7.4% over the forecast period, owing to the increasing patient pool and cost-efficient services.

【レポートの目次】

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Phase
1.1.2. Study design
1.1.3. Cancer type
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1: Understanding the market dynamics
1.9.2. Objective 2: Understanding the market estimates and forecasts
1.9.3. Objective 3: Understanding the attributes such as strategy framework, competitor categorization
1.9.4. Objective 4: Understanding the key product and application scopes to conclude on the market size
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Oncology Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Product Pipeline Analysis, by Stage
3.4. COVID-19 impact on oncology clinical trials
3.5. Market Dynamics
3.5.1. Market Driver Analysis
3.5.1.1. Growing cancer cases worldwide
3.5.1.2. The growing role of precision and personalized medicine for cancer treatment
3.5.1.3. Increased R&D spending towards cancer
3.5.2. Market Restraint Analysis
3.5.2.1. Recruitment obstacles
3.6. Oncology Clinical Trials: Market Analysis Tools
3.6.1. Industry Analysis – Porter’s
3.6.1.1. Supplier Power
3.6.1.2. Buyer Power
3.6.1.3. Substitution Threat
3.6.1.4. Threat from new entrant
3.6.1.5. Competitive rivalry
3.6.2. PESTEL Analysis
3.6.2.1. Political Landscape
3.6.2.2. Environmental Landscape
3.6.2.3. Social Landscape
3.6.2.4. Technology Landscape
3.6.2.5. Legal Landscape
Chapter 4. Oncology Clinical Trials Market: Segment Analysis, by Phase, 2016 – 2027 (USD Million)
4.1. Segment Dashboard
4.2. Phase Market Share Analysis, 2019 & 2027
4.3. Global Oncology Clinical Trials Market, by Phase, 2016 to 2027
4.4. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
4.4.1. Phase I
4.4.2. Phase II
4.4.3. Phase III
4.4.4. Phase IV
Chapter 5. Oncology Clinical Trials Market: Segment Analysis, By Study Design, 2016 – 2027 (USD Million)
5.1. Segment Dashboard
5.2. Study Design Market Share Analysis, 2019 & 2027
5.3. Global Oncology Clinical Trials Market, By Study Design, 2016 to 2027
5.4. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
5.4.1. Interventional
5.4.2. Observational
5.4.3. Expanded Access
Chapter 6. Oncology Clinical Trials Market: Segment Analysis, By Cancer Type, 2016 – 2027 (USD Million)
6.1. Segment Dashboard
6.2. Cancer Type Market Share Analysis, 2019 & 2027
6.3. Global Oncology Clinical Trials Market, By Cancer Type, 2016 to 2027
6.4. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
6.4.1. Lung cancer
6.4.2. Breast cancer
6.4.3. Thyroid cancer
6.4.4. Leukemia
6.4.5. Liver cancer
6.4.6. Skin cancer
6.4.7. Lymphoma
6.4.8. Pancreatic cancer
6.4.9. Prostate cancer
6.4.10. Colon & rectal cancer
6.4.11. Urinary system cancer
6.4.12. Other cancer
Chapter 7. Oncology Clinical Trials Market: Regional Market Analysis, by Phase, 2016 – 2027 (USD Million)
7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2019 & 2027
7.3. Market Size, & Forecasts, and Trend Analysis, 2016 to 2027:
7.4. North America
7.4.1. Market estimates and forecast, by country, 2016 – 2027 (USD Million)
7.4.2. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.4.3. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.4.4. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.4.5. U.S.
7.4.5.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.4.5.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.4.5.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.4.6. Canada
7.4.6.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.4.6.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.4.6.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.5. Europe
7.5.1. Market estimates and forecast, by country, 2016 – 2027 (USD Million)
7.5.2. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.5.3. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.5.4. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.5.5. Germany
7.5.5.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.5.5.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.5.5.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.5.6. U.K.
7.5.6.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.5.6.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.5.6.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.5.7. France
7.5.7.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.5.7.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.5.7.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.5.8. Italy
7.5.8.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.5.8.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.5.8.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.5.9. Spain
7.5.9.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.5.9.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.5.9.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.6. Asia Pacific
7.6.1. Market estimates and forecast, by country, 2016 – 2027 (USD Million)
7.6.2. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.6.3. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.6.4. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.6.5. India
7.6.5.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.6.5.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.6.5.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.6.6. Japan
7.6.6.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.6.6.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.6.6.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.6.7. China
7.6.7.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.6.7.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.6.7.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.6.8. Thailand
7.6.8.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.6.8.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.6.8.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.6.9. South Korea
7.6.9.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.6.9.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.6.9.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.7. Latin America
7.7.1. Market estimates and forecast, by country, 2016 – 2027 (USD Million)
7.7.2. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.7.3. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.7.4. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.7.5. Brazil
7.7.5.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.7.5.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.7.5.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.7.6. Mexico
7.7.6.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.7.6.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.7.6.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.7.7. Argentina
7.7.7.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.7.7.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.7.7.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.7.8. Colombia
7.7.8.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.7.8.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.7.8.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.8. Middle East and Africa
7.8.1. Market estimates and forecast, by country, 2016 – 2027 (USD Million)
7.8.2. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.8.3. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.8.4. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.8.5. South Africa
7.8.5.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.8.5.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.8.5.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.8.6. Saudi Arabia
7.8.6.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.8.6.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.8.6.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
7.8.7. UAE
7.8.7.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.8.7.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.8.7.3. Market estimates and forecast, by cancer type, 2016 – 2027 (USD Million)
Chapter 8. Clinical Trials Market- Competitive Analysis
8.1. Key companies profiled
8.1.1. IQVIA
8.1.1.1. Company Overview
8.1.1.2. Financial Performance
8.1.1.3. Product Benchmarking
8.1.1.4. Strategic Initiatives
8.1.2. PAREXEL International Corporation
8.1.2.1. Company Overview
8.1.2.2. Financial Performance
8.1.2.3. Product Benchmarking
8.1.2.4. Strategic Initiatives
8.1.3. Pharmaceutical Product Development, LLC
8.1.3.1. Company Overview
8.1.3.2. Financial Performance
8.1.3.3. Product Benchmarking
8.1.3.4. Strategic Initiatives
8.1.4. Charles River Laboratory
8.1.4.1. Company Overview
8.1.4.2. Financial Performance
8.1.4.3. Product Benchmarking
8.1.4.4. Strategic Initiatives
8.1.5. ICON Plc
8.1.5.1. Company Overview
8.1.5.2. Financial Performance
8.1.5.3. Product Benchmarking
8.1.5.4. Strategic Initiatives
8.1.6. Syneos Health
8.1.6.1. Company Overview
8.1.6.2. Financial Performance
8.1.6.3. Product Benchmarking
8.1.6.4. Strategic Initiatives
8.1.7. PRA Health Sciences
8.1.7.1. Company Overview
8.1.7.2. Financial Performance
8.1.7.3. Product Benchmarking
8.1.7.4. Strategic Initiatives
8.1.8. Medpace
8.1.8.1. Company Overview
8.1.8.2. Financial Performance
8.1.8.3. Product Benchmarking
8.1.8.4. Strategic Initiatives
8.1.9. Pivotal
8.1.9.1. Company Overview
8.1.9.2. Financial Performance
8.1.9.3. Product Benchmarking
8.1.9.4. Strategic Initiatives
8.1.10. Medelis
8.1.10.1. Company Overview
8.1.10.2. Financial Performance
8.1.10.3. Product Benchmarking
8.1.10.4. Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Oncology Clinical Trials Market, By Region 2016 - 2027 (USD Million)
Table 4 Global Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 5 Global Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 6 Global Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 7 North America Oncology Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
Table 8 North America Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 9 North America Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 10 North America Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 11 U.S. Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 12 U.S. Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 13 U.S. Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 14 Canada Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 15 Canada Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 16 Canada Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 17 Europe Oncology Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
Table 18 Europe Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 19 Europe Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 20 Europe Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 21 U.K. Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 22 U.K. Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 23 U.K. Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 24 Germany Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 25 Germany Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 26 Germany Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 27 France Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 28 France Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 29 France Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 30 Italy Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 31 Italy Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 32 Italy Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 33 Spain Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 34 Spain Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 35 Spain Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 36 Asia Pacific Oncology Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
Table 37 Asia Pacific Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 38 Asia Pacific Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 39 Asia Pacific Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 40 India Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 41 India Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 42 India Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 43 Japan Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 44 Japan Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 45 Japan Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 46 China Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 47 China Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 48 China Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 49 Thailand Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 50 Thailand Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 51 Thailand Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 52 South Korea Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 53 South Korea Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 54 South Korea Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 55 Latin America Oncology Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
Table 56 Latin America Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 57 Latin America Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 58 Latin America Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 59 Brazil Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 60 Brazil Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 61 Brazil Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 62 Mexico Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 63 Mexico Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 64 Mexico Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 65 Argentina Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 66 Argentina Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 67 Argentina Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 68 Colombia Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 69 Colombia Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 70 Colombia Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 71 MEA Oncology Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
Table 72 MEA Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 73 MEA Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 74 MEA Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 75 South Africa Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 76 South Africa Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 77 South Africa Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 78 Saudi Arabia Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 79 Saudi Arabia Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 80 Saudi Arabia Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)
Table 81 UAE Oncology Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 82 UAE Oncology Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 83 UAE Oncology Clinical Trials Market, By Cancer Type, 2016 - 2027 (USD Million)


List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Oncology clinical trials market: Market snapshot
Fig. 9 Oncology clinical trials market: Market segmentation
Fig. 10 Oncology clinical trials market strategy framework
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Oncology clinical trials market driver impact
Fig. 14 Oncology clinical trials market restraint impact
Fig. 15 Oncology clinical trials market Porter's five forces analysis
Fig. 16 Oncology clinical trials market PESTEL analysis
Fig. 17 Oncology clinical trials market segment dashboard
Fig. 18 Oncology clinical trials market: Phase movement Analysis
Fig. 19 Phase I estimates and forecast, 2016 - 2027 (USD Million)
Fig. 20 Phase II estimates and forecast, 2016 - 2027 (USD Million)
Fig. 21 Phase III estimates and forecast, 2016 - 2027 (USD Million)
Fig. 22 Phase IV estimates and forecast, 2016 - 2027 (USD Million)
Fig. 23 Oncology clinical trials market segment dashboard
Fig. 24 Oncology clinical trials market: Study design movement analysis
Fig. 25 Interventional market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 26 Observational market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 27 Expanded Access market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 28 Oncology clinical trials market: Segment dashboard
Fig. 29 Oncology clinical trials market: Cancer type movement analysis
Fig. 30 Lung cancer market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 31 Breast cancer market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 32 Thyroid cancer market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 33 Leukemia market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 34 Liver cancer market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 35 Skin cancer market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 36 Lymphoma market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 37 Pancreatic cancer market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 38 Prostate cancer market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 39 Colorectal cancer market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 40 Urinary system cancer market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 41 Other cancer market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 42 Global oncology clinical trials market: Regional movement analysis
Fig. 43 Global oncology clinical trials market: Regional outlook and key takeaways
Fig. 44 Global market share, by region
Fig. 45 North America market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 46 U.S. market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 47 Canada market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 48 Europe market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 49 U.K. market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 50 Germany market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 51 France market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 52 Italy market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 53 Spain market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 54 Asia Pacific market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 55 India market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 56 Japan market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 57 China market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 58 Thailand market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 59 South Korea market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 60 Latin America market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 61 Brazil market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 62 Mexico market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 63 Argentina market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 64 Colombia market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 65 Middle East and Africa. market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 66 South Africa market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 67 Saudi Arabia market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 68 UAE market estimates and forecast, 2016 - 2027 (USD Million)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[腫瘍臨床試験の世界市場2020-2027:フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV)、研究デザイン別(介入、観察、アクセス拡大)、がん種類別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆